- In October 2021, Gynesonics, a company dedicated to developing minimally invasive solutions for symptomatic uterine fibroids, announced that Dr. John Thoppil became the first physician in Texas to provide its Sonata treatment. This innovative procedure is now available to women with symptomatic uterine fibroids at his River Place OB/GYN facility in Austin, Texas. By offering this office-based solution, Dr. Thoppil aims to enhance patient care and provide an effective alternative for managing uterine fibroids
- In September 2021, Gynesonics, a company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced that the Food and Drug Administration (FDA) granted clearance for the Sonata® System 2.2. This updated system introduces significant new benefits for healthcare facilities, physicians, and patients alike. The approval underscores Gynesonics' commitment to advancing treatment options for women suffering from uterine fibroids, enhancing both the efficacy and accessibility of care
- In October 2021, Hologic, Inc. acquired Bolder Surgical, a privately held U.S. company recognized for its cutting-edge energy vessel sealing surgical devices. This acquisition not only broadened Hologic's surgical portfolio but also enhanced its competitive position in the healthcare market. By integrating Bolder Surgical's innovative technologies, Hologic aims to strengthen its offerings and improve surgical outcomes for patients
- In August 2021, Hologic, Inc., a leading global company in women's health, announced that Anthem Blue Cross Blue Shield, the second-largest health plan in the U.S., revised its medical policy to include coverage for radiofrequency ablation (LAP-RFA). This update specifically encompasses the Acessa procedure (CPT Code 58674) for women experiencing uterine fibroids. The decision to expand coverage reflects a growing recognition of the need for effective treatment options for this common condition, ultimately improving access to care for affected patients
- In August 2020, Hologic Inc. completed the acquisition of Acessa Health Inc., a private company renowned for its focus on minimally invasive therapies for uterine fibroids. This strategic acquisition strengthened Hologic's product offerings in the fibroid treatment market, allowing them to provide a broader range of innovative solutions. By integrating Acessa Health's expertise and technologies, Hologic aims to enhance patient care and improve treatment outcomes for women suffering from fibroids
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Robotic Myomectomy, Abdominal Myomectomy, Hysteroscopic Myomectomy, and Laparoscopic Myomectomy), Product (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer, and Others), End User (Hospitals, Ambulatory Surgical Centers, Clinics, and Medical Device Companies) – Industry Trends and Forecast to 2031
.
The Global Myomectomy Market size was valued at USD 758.52 USD Million in 2023.
The Global Myomectomy Market is projected to grow at a CAGR of 8.67% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
